Cost-effectiveness of bendamustine versus fludarabine for first-line treatment of chronic lymphocytic leukemia (Cll) in Colombia

Abstract:

Objectives To determine the cost-effectiveness of bendamustine versus fludarabine for first line treatment of CLL in Colombia. Methods An economic model was constructed from the Colombian health system perspective, with a 25-year (lifetime) horizon and a discount rate of 3%. The model included three health states, progression-free (PF), progressive disease (PD), and death. Clinical inputs (Kaplan-Meier curves, response rates, hazard ratios (HRs) and adverse event (AE) rates) were from a phase 3 trial comparing bendamustine and chlorambucil, and from a network meta-analysis. Resource use data were from interviews with three Colombian hematologists treating CLL. Resource use for PF patients was weighted based on treatment response. Unit costs were from ISS and SISPRO report and were expressed in 2013 Colombian Pesos. Univariate and probabilistic sensitivity analyses were conducted to …

Año de publicación:

2013

Keywords:

Fuente:

google